The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial

摘要: Background Recurrent aphthous ulceration (RAU) is the most common oral mucosal disease. Some patients have almost continuous ulcers which influence quality of life. The aim this study was to observe efficacy and safety thalidomide on recurrence interval RAU. Methods A randomized controlled clinical trial designed, 60 RAU were randomly assigned experimental group (n = 32, taking before bed at a dose 100 mg/d for 10 days, then 50 25 days) control 28, 0.4 mg/kg/d prednisone every morning 15 days 0.2 days). outcomes consisted primary outcome (recurrence interval) secondary (pain level, number ulcers, ulcer healing), they measured visit. Adverse reactions recorded. Results total 54 51 presented first second return visit, respectively. After 1 month, increase in not shown differ between two groups (P .12). However, improvement significantly greater .05). incidence adverse similar .50). Conclusions Thalidomide had long-term effect extending